The KEYNOTE studies used the 22C3 PD-L1 immunohistochemistry assay (Agilent, Carpinteria, CA) to calculate a CPS estimated as the ratio of PD-L1-positive cells (tumor cells plus immune cells divided by the total number of viable tumor cells ×100 with a cut-off ≥10 [59, 73]). The gene discussed is CD274; the disease is neoplasm.